Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Denali Therapeutics (DNLI) Operating Income (2017 - 2025)

Denali Therapeutics (DNLI) has disclosed Operating Income for 9 consecutive years, with -$137.4 million as the latest value for Q4 2025.

  • On a quarterly basis, Operating Income fell 5.79% to -$137.4 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$555.3 million, a 13.95% decrease, with the full-year FY2025 number at -$555.3 million, down 13.95% from a year prior.
  • Operating Income was -$137.4 million for Q4 2025 at Denali Therapeutics, roughly flat from -$137.4 million in the prior quarter.
  • In the past five years, Operating Income ranged from a high of $170.5 million in Q2 2023 to a low of -$145.6 million in Q1 2025.
  • A 5-year average of -$93.8 million and a median of -$115.2 million in 2023 define the central range for Operating Income.
  • Peak YoY movement for Operating Income: skyrocketed 377.59% in 2023, then tumbled 168.39% in 2024.
  • Denali Therapeutics' Operating Income stood at -$77.1 million in 2021, then plummeted by 36.6% to -$105.3 million in 2022, then decreased by 25.85% to -$132.6 million in 2023, then grew by 2.06% to -$129.8 million in 2024, then fell by 5.79% to -$137.4 million in 2025.
  • Per Business Quant, the three most recent readings for DNLI's Operating Income are -$137.4 million (Q4 2025), -$137.4 million (Q3 2025), and -$135.0 million (Q2 2025).